A PHASE III OPEN LABEL STUDY CONTROLLED BY VITAMIN D3 SUPPLEMENTATION AND THE DIFFERENCES BETWEEN YOUNG ADULTS AND SENIOR POPULATION

Status

Withdrawn

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-511889-36-01

Acronym

D3-2024

Enrollment

150

Registered

2024-10-25

Start date

Unknown

Completion date

Unknown

Last updated

2024-10-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy population

Brief summary

Primary e nd point is Serum 25 hydroxycholecalciferol.

Detailed description

Secondary e nd p oints are Serum 24,25 dihydroxycholecalciferol levels and Serum 3 epi 25 hydroxycholecalciferol levels.

Interventions

DRUGVigantol 0

DRUG5 mg/ml perorální kapky

DRUGroztok

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Primary e nd point is Serum 25 hydroxycholecalciferol.	—

Secondary

Measure	Time frame
Secondary e nd p oints are Serum 24,25 dihydroxycholecalciferol levels and Serum 3 epi 25 hydroxycholecalciferol levels.	—

Countries

Czechia

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026